Laurus Labs Q4 Profit Surges to ₹234 Crore

25 Apr 2025 , 04:20 PM

Laurus Labs Ltd posted a healthy financial performance in the fourth quarter ended March 2025 with profit and operating numbers surpassing street estimates. The net profit of the company increased to ₹233.6 crore, three times the ₹75.6 crore posted in the same quarter last year.

Laurus Labs’ EBITDA increased 74% year-on-year to ₹419 crore. EBITDA margins too saw a steep rise, rising by almost 800 basis points to 24.5%, from 16.7% in the same quarter last year. Contract Development and Manufacturing Organisation (CDMO) business also saw remarkable growth, rising by 85% over the last year, with revenue at ₹490 crore.

Finished Dosage Formulations (FDF) business also saw a 27% growth, while the Generics business saw moderate growth of 5%. But the Active Pharmaceutical Ingredients (API) business fell 8%, helping to offset gains elsewhere.

Founder and CEO Dr. Satyanarayana Chava indicated Laurus Labs is going in a steady direction towards becoming a diversified CDMO player with deep technology platforms and commercial capabilities.

CFO VV Ravi Kumar reaffirmed the company’s capital allocation thesis by indicating Laurus will keep investing in high-value business opportunities to support long-term growth. Management is optimistic of accelerating revenue growth in FY26, supported by new asset ramp-ups and a solid order book.